V-Card | Print | PDF | Email Page

Tamera M. Weisser Ph.D. (Tammy)
Partner

Contact

(T) +1.858.314.1181
(F) +1.844.345.3178

Education

  • Georgetown University (J.D. 2004); University of Massachusetts Medical School (Ph.D. in Immunology and Virology 2000); University of Wisconsin-Madison (B.S. in Molecular Biology 1993)

Bar Admissions

  • California, U.S. Supreme Court, U.S. District Court for the Southern District of California, U.S. Court of Appeals for the Federal Circuit, and registered to practice before the U.S. Patent and Trademark Office

Dr. Tamera (Tammy) Weisser is co-leader of Jones Day's global patent prosecution group, comprising more than 100 professionals worldwide. She has nearly 20 years of experience in global patent portfolio development, management, and enforcement in biotechnology, particularly in the areas of biologics and diagnostics. For example, on behalf of NGM Biopharmaceuticals, Tammy coordinates the implementation of a global patent strategy concerning various novel protein and antibody therapeutics in clinical trials for the treatment of diabetes, NASH (nonalcoholic steatohepatitis), and other metabolic disorders. On behalf of BioMarin, she established a worldwide patent portfolio for Pegvaliase, an enzyme replacement therapy in clinical trials for phenylketonuria treatment. She has developed IP strategies for dozens of antibody therapeutics for clients, including Celgene, Kyowa Hakko Kirin, and MedImmune (AstraZeneca). Commercial products for which Tammy has experience include EmboSpheres®, HepaSpheres®, Humira®, Kynamro®, Otezla®, Pomalyst®, Revlimid®, and Synagis®.

Her practice also includes performing patent validity and freedom-to-operate analyses and conducting due diligence of patent portfolios for clients, including potential investors, acquirers, and licensees. She has been involved in a number of oppositions before the European Patent Office as well as interferences.

In addition, Tammy has in-depth experience in inter partes review (IPR) proceedings. She successfully defended AbbVie in two IPRs brought by Amgen and a third IPR brought by Coherus in connection with patents related to AbbVie's blockbuster antibody therapeutic Humira®, in which the Patent Trial and Appeal Board (PTAB) denied institution.

Tammy served on the board of directors of several local professional organizations, and she is consistently recognized as being a top attorney and for her leadership and contribution within the community.


Honors & Distinctions

  • 2017: "Top 100 Women Lawyers in California," The Daily Journal

    2017: "Most Influential Women in San Diego," The Daily Transcript

    2016-2017: Recommended Lawyer, Legal 500 US

    2016-2017: Super Lawyers, San Diego

    2014-2016: "Best of the Bar," San Diego Business Journal

    2013: "Women Who Mean Business" Award, San Diego Business Journal

    2012: Athena Pinnacle Award
Tamera Weisser Tammy